Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Tr...

por Strøm, Hans H., Bremnes, Roy M., Sundstrøm, Stein H., Helbekkmo, Nina, Aasebø, Ulf
Publicado 2014

Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis

por Norum, Jan, Antonsen, Margareth Aarag, Tollåli, Terje, Al-Shibli, Khalid, Andersen, Gry, Svanqvist, Kristin Helene, Helbekkmo, Nina
Publicado 2017

Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial

por Horndalsveen, Henrik, Alver, Tine Norman, Dalsgaard, Astrid Marie, Rogg, Lotte Victoria, Helbekkmo, Nina, Grønberg, Bjørn Henning, Halvorsen, Tarje Onsøien, Ramberg, Christina, Haakensen, Vilde Drageset, Öjlert, Åsa Kristina, Bjaanæs, Maria Moksnes, Helland, Åslaug
Publicado 2022